Literature DB >> 15667496

Visceral sensitivity and symptoms in patients with constipation- or diarrhea-predominant irritable bowel syndrome (IBS): effect of a low-fat intraduodenal infusion.

Maria Pia Caldarella1, Angelo Milano, Francesco Laterza, Flora Sacco, Crysanthi Balatsinou, Domenico Lapenna, Sante Donato Pierdomenico, Franco Cuccurullo, Matteo Neri.   

Abstract

BACKGROUND: Visceral hypersensitivity is common in Irritable Bowel Syndrome (IBS) patients, and symptoms exacerbate postprandially. Yet the effects of nutrients on visceral sensitivity and symptoms in these patients have not been fully explored. AIMS: To evaluate the differences of visceral sensitivity and symptoms in healthy subjects and IBS patients during fasting and intraduodenal lipids infusion.
METHODS: Graded rectal distensions at fixed tension levels were performed in 16 IBS patients (8 IBS-C and 8 IBS-D) and 6 healthy subjects before and during intraduodenal lipids infusion at 0.5 kcal/min. Tension levels were increased in 4 gr increments up to 64 gr or discomfort during both conditions. At each step, perception and symptoms were measured by means of a validated questionnaire.
RESULTS: In basal conditions, perception thresholds in IBS patients and health were, respectively, 8 +/- 2 gr versus 32 +/- 9 gr (p < 0.001) with no changes during lipids. Intraduodenal lipids infusion significantly lowered threshold of discomfort in IBS patients in comparison to fasting (24 +/- 6 gr vs 34 +/- 4 gr; p < 0.05), while health tolerated all distension without discomfort. No differences of compliance, perception, or discomfort were observed between the two subgroups of patients at each tension step. The predominant symptom elicited in patients with IBS-C was abdominal pain (54%), while patients with IBS-D exhibited urgency (63%, p < 0.005); this pattern was maintained during lipids.
CONCLUSIONS: Intraduodenal lipids increase visceral sensitivity in both IBS-C and IBS-D; symptoms specificity in response to rectal distension is maintained in the postprandial period. Lipids may be responsible for the postprandial symptoms exacerbation in IBS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667496     DOI: 10.1111/j.1572-0241.2005.40100.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  19 in total

Review 1.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

Review 2.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

3.  Effect of 5-HT1 agonist (sumatriptan) on anorectal function in irritable bowel syndrome patients.

Authors:  Agata Mulak; Leszek Paradowski
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

Review 4.  Functional findings in irritable bowel syndrome.

Authors:  Iris Posserud; Amanda Ersryd; Magnus Simrén
Journal:  World J Gastroenterol       Date:  2006-05-14       Impact factor: 5.742

Review 5.  Novel techniques to study visceral hypersensitivity in irritable bowel syndrome.

Authors:  Trinh T Truong; Bruce D Naliboff; Lin Chang
Journal:  Curr Gastroenterol Rep       Date:  2008-08

6.  Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits.

Authors:  Motoyori Kanazawa; Olafur S Palsson; Syed I M Thiwan; Marsha J Turner; Miranda A L van Tilburg; Lisa M Gangarosa; Denesh K Chitkara; Shin Fukudo; Douglas A Drossman; William E Whitehead
Journal:  Am J Gastroenterol       Date:  2008-08-05       Impact factor: 10.864

7.  Dietary Renaissance in IBS: Has Food Replaced Medications as a Primary Treatment Strategy?

Authors:  Marisa Spencer; William D Chey; Shanti Eswaran
Journal:  Curr Treat Options Gastroenterol       Date:  2014-12

8.  Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls.

Authors:  Iris Posserud; Hans Strid; Stine Störsrud; Hans Törnblom; Ulla Svensson; Jan Tack; Lukas Van Oudenhove; Magnus Simrén
Journal:  United European Gastroenterol J       Date:  2013-10       Impact factor: 4.623

Review 9.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

Review 10.  Guidelines on the irritable bowel syndrome: mechanisms and practical management.

Authors:  R Spiller; Q Aziz; F Creed; A Emmanuel; L Houghton; P Hungin; R Jones; D Kumar; G Rubin; N Trudgill; P Whorwell
Journal:  Gut       Date:  2007-05-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.